导师介绍


姜新义 教授
作者:  来源:  发布时间:2018年02月06日 11:17  浏览次数:

 

一、基本情况

姜新义2017年加盟山东大学药学院,被聘为齐鲁学者,教授/博士生导师,从事药剂学教学科研工作。目前已独立主持人主持中国和美国多项科研基金,在PNASBiomaterialsTheranostics等综合性期刊或药剂学专业期刊上已发表SCI论文26篇,累计影响因子大于160,总引用超过1500余次, H-index 17,已获得授权发明专利2项。多次应邀在Society for Biomaterials (SFB,生物材料年会)Biomedical Engineering Society (BMES,生物医学工程年会,Orthopedic Research Society (ORS,骨科年会)等国际会议上做大会报告。

通讯地址:山东省济南市文化西路44号,山东大学药学院药剂教研室

TEL: 0531-88382015Cell-phone+86-15662758621

FAX: 0531-88372015

Emai:xinyijiang@sdu.edu.cn

 

二、研究领域

1.    基于纳米医学的原位及脑转移肿瘤的诊断治疗;

2.    基于干细胞的肿瘤基因治疗;

3.    骨或软骨再生的组织工程学研究

 

三、工作及学习经历

1.    工作经历

201711-至今山东大学药学院,齐鲁学者,教授/博士生导师;

20134-201710月,美国斯坦福大学医学院,博士后研究员;

20126-20144月江苏大学药学院,药剂学教研室,硕士生导师;

2.    学习经历

20099-20126月复旦大学药剂学,博士研究生;

20069-20097月中国药科大学中药制剂,硕士研究生;

20029-20097月山东中医药大学制药工程,本科

 

四、社会兼职

1.    学术会议会员

Society for Biomaterials (生物材料协会)2015-2016

Biomedical Engineering Society (生物医学工程协会)2015-20162017-至今

Orthopedic Research Society (骨科协会), 2015-2016

2.    期刊编委:

Mathews Journal of Orthopedics2016-至今

Integrated Medical and Clinical Case Reports2017-至今

Heighpubs Clinical and Experimental Orthopaedics2017-至今

British Journal of Orthopedics and Sports Medicine2017-至今

3.    SCI期刊特邀审稿:

Biomaterials2012-至今

Journal of controlled release2015-至今

Internal Medicine Journal2016-至今

Nanoscale2016-至今

Medicine2016-至今

Molecular Pharmaceutics2016-至今

International Journal of Nanomedicine2016-至今

International Journal of Pharmaceutics; 2016-至今

Tissue engineering Part A2016-至今

Cellular & Molecular biology2016-至今

 

五、教学工作

药剂学,药用高分子材料,药物代谢与动力学

 

六、承担课题

1.    主持中国国家自然科学基金青年项目,2014-2016;

2.    主持Stanford Child Health Research Institute (CHRI) Grant Award, 2014-2015;

3.    主持Stanford School of Medicine Dean’s postdoctoral fellowships, 2013-2014;

4.    Co-PI,leading Alliance for Cancer Gene Therapy (ACGT) funding,2014-2017

5.    山东大学齐鲁青年学者启动基金;

另外参与完成了多项美国NIHRO1基金;参与完成了中国973重大基础科研创新项目和国家重大新药创制临床前研究部分工作。

 

七、代表性文章

1. Xinyi Jiang, Sergio Fitch, Christine Wang, Christy Wilson, Jianfeng Li, Gerald Grant and Fan Yang*. Nanoparticle engineered TRAIL-overexpressing adipose-derived stem cells target and eradicate glioblastoma via intracranial delivery. Proceedings of the National Academy of Sciences U.S.A (PNAS),2016 113 (48) 13857-13862.

2. Xinyi Jiang, Christine Wang, Sergio Fitch, Fan YangTargeting Tumor Hypoxia Using Nanoparticle-engineered CXCR4-overexpressing Adipose-derived Stem CellsTheranostics2018; 8(5): 1350-1360. (IF: 8.766)

3. Xinyi Jiang, Hongliang Xin, JijinGu, Ximing Xu, Weiyi Xia, Shuo Chen, YikeXie, Liangcen Chen, Yanzuo Chen, Xianyi Sha, Xiaoling Fang. Solid tumor penetration by integrin-mediated pegylatedpoly(trimethylene carbonate) nanoparticles loaded with pactlitaxel. Biomaterials. 2013, 34: 1739-1746. (IF: 8.387)

4. Xinyi Jiang; Hongliangxin; Qiuyue Ren; JijinGu; Lingjun Zhu; Fengyi Du; Chunlai Feng; YikeXie; Xianyi Sha; Xiaoling Fang, Nanoparticles of 2-deoxy-D-glucose functionalized poly(ethylene glycol)-co-poly(trimethylene carbonate) for dual-targeted drug delivery in glioma treatment. Biomaterials. 2014,35(1): 518-29. (IF: 8.557)

5.   Xinyi Jiang, Xianyi Sha, Hongliang Xin, Ximing Xu, JijinGu, Weiyi Xia, Shuo Chen, YikeXie, Liangcen Chen, Yanzuo Chen, Xiaoling Fang. Integrin-facilitated transcytosis for enhanced penetration of advanced gliomas by poly(trimethylene carbonate)-based nanoparticles encapsulating paclitaxel. Biomaterials.2013, 23(4): 2969-2979. (IF: 8.557)

6. Xinyi Jiang, Xianyi Sha, Hongliang Xin, Liangcen Chen, Xihui Gao, Xiao Wang, Kitki Law, JijinGu, Yanzuo Chen, Ye Jiang, Xiaoqing Ren, Qiuyue Ren, Xiaoling Fang. Self-aggregated pegylated poly (trimethylene carbonate) nanoparticles decorated with c(RGDyK) peptide for targeted paclitaxel delivery to integrin-rich tumors. Biomaterials. 2011, 32: 9457-9469. (IF: 8.557)

7. Xinyi Jiang, Hongliang Xin, Xianyi Sha, JijinGu, Ye Jiang, Law Kitki, Yanzuo Chen, Liangcen Chen, Xiao Wang, Xiaoling Fang. PEGylated poly (trimethylene carbonate) nanoparticles loaded with paclitaxel for the treatment of advanced glioma: in vitro and in vivo evaluation. International Journal of Pharmaceutics. 2011, 420(2): 385-394. (IF: 3.65)

8. Xinyi Jiang; Hongliangxin; JijinGu; Fengyi Du; Chunlai Feng; YikeXie; Xiaoling Fang, Enhanced anti-tumor efficacy by D-glucosamine functionalized and paclitaxel loaded poly(ethylene glycol)-co-poly(trimethylene carbonate) polymer nanoparticles. Journal of Pharmaceutical Sciences. 2014, 103(5): 1487-1496. (IF: 2.59)

9. Xinyi Jiang, Taishi Sato, Zhenyu Yao, Michael Keeney, JukkaPajarinen, Tzu-hua Lin, Florence Loi, Kensuke Egashira, Stuart Goodman, and Fan Yang. Local delivery of mutant CCL2 protein reduced orthopaedic implant wear particle-induced osteolysis and inflammation in vivo. Journal of Orthopeadic Research, 2016;34(1):58-64. (IF: 2.986)

10. Xin Hongliang, Jiang xinyi, Gujijin, Sha xianyi, Chen liangcen, Law kitty, Chen yanzuo, Wang xiao, Jiang ye, Xiaoling Fang. Angiopep-conjugated poly(ethylene glycol)-co-poly(ε-caprolactone) nanoparticles as dual-targeted drug delivery system for brain glioma. Biomaterials. 2011, 32(18): 4293-4305. (IF: 8.557)

 

八、获得专利

授权专利1:一种包载紫杉醇的生物可降解纳米复合物及其制备方法。发明人:方晓玲,姜新义,沙先谊;专利号:201110174751.1;

授权专利2:一种靶向整合素受体的紫杉醇纳米复合物及其制备方法和应用。发明人:方晓玲,姜新义,沙先谊;专利号:201110174752.6.

 

九、成果

2014     Stanford Child Health Research Institute (CHRI) Grant & Postdoctoral Award $50,000;

2013     Stanford Dean’s Postdoctoral Fellowships ($23,200);

2011     中国药学大会优秀论文二等奖

 

拟招收研究生情况

•      课题组每年招收博士后1名,博士生1名,硕士生2名,本科生不限,欢迎感兴趣的同学与我联系。

•      We are recruiting postdocs, Ph.D and master students, if interested, fell free to contact me at xinyijiang@sdu.edu.cn.

 

 
上一条:孙淑娟 主任药师
下一条:宋淳 教授

关闭


版权所有:山东大学药学院 Copyright © 2017 地址:济南市文化西路44号 电话:0531-88382017 传真:0531-88382548 E-mail:pharma@sdu.edu.cn